CU20150174A7 - Método para generar una composición farmacéutica purificada de un complejo de radionúclido emisor alfa - Google Patents
Método para generar una composición farmacéutica purificada de un complejo de radionúclido emisor alfaInfo
- Publication number
- CU20150174A7 CU20150174A7 CUP2015000174A CU20150174A CU20150174A7 CU 20150174 A7 CU20150174 A7 CU 20150174A7 CU P2015000174 A CUP2015000174 A CU P2015000174A CU 20150174 A CU20150174 A CU 20150174A CU 20150174 A7 CU20150174 A7 CU 20150174A7
- Authority
- CU
- Cuba
- Prior art keywords
- complex
- generating
- radionucclid
- issuer
- alfa
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000011230 binding agent Substances 0.000 abstract 3
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Saccharide Compounds (AREA)
- Extraction Or Liquid Replacement (AREA)
Abstract
Un método para generar una solución purificada de por lo menos un complejo de radionúclido emisor alfa. El método comprende poner en contacto una solución del complejo de radionúclido emisor alfa y por lo menos un núclido hijo que tiene por lo menos un ligante selectivo para los núclidos hijos y subsiguientemente separar la solución del ligante selectivo. También, un método para preparar por lo menos un radionúclido hijo de una solución que comprende por lo menos un complejo de radionúclido emisor alfa. El método comprende poner en contacto la solución que tiene por lo menos un ligante selectivo para los núclidos hijos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1310028.4A GB201310028D0 (en) | 2013-06-05 | 2013-06-05 | Pharmaceutical preparation |
| PCT/EP2014/061743 WO2014195423A1 (en) | 2013-06-05 | 2014-06-05 | Pharmaceutical preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20150174A7 true CU20150174A7 (es) | 2016-06-29 |
| CU24535B1 CU24535B1 (es) | 2021-07-02 |
Family
ID=48805787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2015000174A CU24535B1 (es) | 2013-06-05 | 2014-06-05 | Método para generar una solución purificada de un isótopo de torio emisor alfa |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US20160114063A1 (es) |
| EP (1) | EP3003401B1 (es) |
| JP (1) | JP6580559B2 (es) |
| KR (1) | KR102321763B1 (es) |
| CN (1) | CN105592863B (es) |
| AP (1) | AP2015008894A0 (es) |
| AU (1) | AU2014276885B2 (es) |
| BR (1) | BR112015030298A2 (es) |
| CA (1) | CA2914278C (es) |
| CL (1) | CL2015003554A1 (es) |
| CR (1) | CR20150642A (es) |
| CU (1) | CU24535B1 (es) |
| DK (1) | DK3003401T3 (es) |
| DO (1) | DOP2015000294A (es) |
| EA (1) | EA201501174A1 (es) |
| ES (1) | ES2782624T3 (es) |
| GB (1) | GB201310028D0 (es) |
| HR (1) | HRP20200456T1 (es) |
| IL (1) | IL242704B (es) |
| LT (1) | LT3003401T (es) |
| MA (1) | MA38650B1 (es) |
| MX (1) | MX366028B (es) |
| MY (1) | MY180717A (es) |
| NI (1) | NI201500173A (es) |
| PE (1) | PE20160215A1 (es) |
| PH (1) | PH12015502715A1 (es) |
| PL (1) | PL3003401T3 (es) |
| PT (1) | PT3003401T (es) |
| RS (1) | RS60091B1 (es) |
| SA (1) | SA515370233B1 (es) |
| SG (1) | SG11201509856RA (es) |
| SI (1) | SI3003401T1 (es) |
| TN (1) | TN2015000527A1 (es) |
| UA (1) | UA120352C2 (es) |
| WO (1) | WO2014195423A1 (es) |
| ZA (1) | ZA201600027B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201600161D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Isotope purification method |
| GB201600158D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Purification method |
| JP7544819B2 (ja) | 2019-12-05 | 2024-09-03 | サイエンコンス アクスイェ セルスカプ | 高度に精製された２１２Ｐｂの製造 |
| CN116745323A (zh) | 2021-01-22 | 2023-09-12 | 拜耳股份有限公司 | Lrrc15抗体及其缀合物 |
| NO347755B1 (en) * | 2021-10-21 | 2024-03-18 | Blue Wave Therapeutics Gmbh | Peptide-coupled alginate gels comprising radionuclides |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5749042A (en) * | 1997-01-28 | 1998-05-05 | Battelle Memorial Institute | Bismuth generator method |
| GB0308731D0 (en) * | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| EP2424875B1 (en) * | 2009-04-29 | 2016-01-06 | Bio-Rad Laboratories, Inc. | Purification of immunoconjugates |
| GB201002508D0 (en) | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201105298D0 (en) * | 2011-03-29 | 2011-05-11 | Algeta Asa | Pharmaceutical preparation |
-
2013
- 2013-06-05 GB GBGB1310028.4A patent/GB201310028D0/en not_active Ceased
-
2014
- 2014-06-05 UA UAA201512920A patent/UA120352C2/uk unknown
- 2014-06-05 LT LTEP14728571.2T patent/LT3003401T/lt unknown
- 2014-06-05 CN CN201480044621.8A patent/CN105592863B/zh not_active Expired - Fee Related
- 2014-06-05 KR KR1020157036893A patent/KR102321763B1/ko not_active Expired - Fee Related
- 2014-06-05 PT PT147285712T patent/PT3003401T/pt unknown
- 2014-06-05 PL PL14728571T patent/PL3003401T3/pl unknown
- 2014-06-05 CA CA2914278A patent/CA2914278C/en active Active
- 2014-06-05 SI SI201431535T patent/SI3003401T1/sl unknown
- 2014-06-05 WO PCT/EP2014/061743 patent/WO2014195423A1/en not_active Ceased
- 2014-06-05 DK DK14728571.2T patent/DK3003401T3/da active
- 2014-06-05 MY MYPI2015704399A patent/MY180717A/en unknown
- 2014-06-05 MX MX2015016726A patent/MX366028B/es active IP Right Grant
- 2014-06-05 TN TN2015000527A patent/TN2015000527A1/en unknown
- 2014-06-05 CU CU2015000174A patent/CU24535B1/es unknown
- 2014-06-05 BR BR112015030298A patent/BR112015030298A2/pt active Search and Examination
- 2014-06-05 RS RS20200349A patent/RS60091B1/sr unknown
- 2014-06-05 US US14/896,424 patent/US20160114063A1/en not_active Abandoned
- 2014-06-05 AU AU2014276885A patent/AU2014276885B2/en not_active Ceased
- 2014-06-05 SG SG11201509856RA patent/SG11201509856RA/en unknown
- 2014-06-05 PE PE2015002566A patent/PE20160215A1/es unknown
- 2014-06-05 EP EP14728571.2A patent/EP3003401B1/en active Active
- 2014-06-05 HR HRP20200456TT patent/HRP20200456T1/hr unknown
- 2014-06-05 MA MA38650A patent/MA38650B1/fr unknown
- 2014-06-05 AP AP2015008894A patent/AP2015008894A0/xx unknown
- 2014-06-05 JP JP2016517608A patent/JP6580559B2/ja not_active Expired - Fee Related
- 2014-06-05 EA EA201501174A patent/EA201501174A1/ru unknown
- 2014-06-05 ES ES14728571T patent/ES2782624T3/es active Active
-
2015
- 2015-11-22 IL IL242704A patent/IL242704B/en active IP Right Grant
- 2015-12-03 SA SA515370233A patent/SA515370233B1/ar unknown
- 2015-12-04 CR CR20150642A patent/CR20150642A/es unknown
- 2015-12-04 CL CL2015003554A patent/CL2015003554A1/es unknown
- 2015-12-04 PH PH12015502715A patent/PH12015502715A1/en unknown
- 2015-12-04 DO DO2015000294A patent/DOP2015000294A/es unknown
- 2015-12-04 NI NI201500173A patent/NI201500173A/es unknown
-
2016
- 2016-01-04 ZA ZA2016/00027A patent/ZA201600027B/en unknown
-
2021
- 2021-05-04 US US17/307,857 patent/US20220023449A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP18053055A (es) | Agonista triple de receptores de glucagón/glp-1/gip | |
| CR20160257A (es) | Anticuerpos e inmunoconjugados anti-cd33 | |
| MX2018009876A (es) | Encapsulamiento y desencapsulamiento de medios. | |
| NI201700167A (es) | Terapias combinadas para hemo malignidades con anticuerpos anti-cd38 e inhibidores de survivina | |
| MX2018005551A (es) | Anticuerpos que se unen especificamente a pd-1, y sus usos. | |
| UY35589A (es) | Compuesto peptídico | |
| ECSP17010156A (es) | Compuestos aminopirimidinilo como inhibidores jak | |
| MX2017016676A (es) | Composicion envasada. | |
| CR20150049A (es) | Anticuerpos e inmunoconjugados anti-cd79b | |
| ECSP17084635A (es) | Moduladores cot y métodos de uso de los mismos | |
| CL2017003163A1 (es) | Nuevos derivados aminoácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| AR097627A1 (es) | Métodos y dispositivos para la codificación conjunta de canales múltiples | |
| CL2018000371A1 (es) | Complejos de anillos macrocíclicos de pentaaza que poseen biodisponibilidad oral. | |
| CR20150642A (es) | Preparado farmaceutico | |
| CU20160069A7 (es) | Sistema multiparticulado para administrar drogas | |
| DK3167026T3 (da) | Alkyleringsfremgangsmåde der anvender en katalysator, som omfatter sjælden jord rigt på cerium, der indeholder zeolitter og et hydrogeneringsmetal. | |
| BR112017002139A2 (pt) | ?método para preparar um composto? | |
| MX2016007592A (es) | Composicion que comprende agente beneficioso y solvente aprotico. | |
| UY35823A (es) | Profármacos de antagonista de nmda | |
| MX2019015603A (es) | Encapsulamiento de guia de servicios. | |
| FR3025354B1 (fr) | Creation d'isotopes par reactions nucleaires en chaine | |
| MX2016016417A (es) | Autorizacion de union de instancias de cadena de transformacion. | |
| PL407052A1 (pl) | Sposób utwardzania żywicy epoksydowej z wykorzystaniem bis(heptaizooktyloglinosilseskwioksanu) | |
| CO7141421A2 (es) | Formulación farmacéutica que tiene estabilidad mejorada |